Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2025-12-05 00:00:00 ET · period of report 2025-12-03 · accession 0000875320-25-000242 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-12-05 | 2025-12-03+ | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | M - OptEx | $86.52 | +63.8K | 87.8K | +265% | +$5.52M |
| DM | 2025-12-05 | 2025-12-03 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | S - Sale+OE | $449.20 | -63.8K | 75.2K | -46% | -$28.65M |
| DM | 2025-12-05 | 2025-12-03+ | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | M - OptEx | $0.00 | -63.8K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-04 | M | A | 1 | $91.05 | 24,027 | D | — | — | |
| 2 | Common | Common Stock | 2025-12-03 | S | D | 7,899 | $445.56 | 67,298 | D | — | — | (F7) Open market sales reported on this line occurred at a weighted average price of $445.56 (range $445.00 to $445.82). (F2) Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2025-12-03 | S | D | 10,360 | $453.34 | 26,096 | D | — | — | (F13) Open market sales reported on this line occurred at a weighted average price of $453.34 (range $452.91 to $453.70). (F2) Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 4 | Common | Common Stock | 2025-12-03 | S | D | 15,681 | $452.20 | 36,456 | D | — | — | (F12) Open market sales reported on this line occurred at a weighted average price of $452.20 (range $451.73 to $452.69). (F2) Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 5 | Common | Common Stock | 2025-12-03 | S | D | 5,809 | $451.20 | 52,137 | D | — | — | (F11) Open market sales reported on this line occurred at a weighted average price of $451.20 (range $450.71 to $451.70). (F2) Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 6 | Common | Common Stock | 2025-12-03 | S | D | 5,880 | $449.84 | 57,946 | D | — | — | (F10) Open market sales reported on this line occurred at a weighted average price of $449.84 (range $449.22 to $450.18). (F2) Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 7 | Common | Common Stock | 2025-12-03 | S | D | 2,320 | $448.78 | 63,826 | D | — | — | (F9) Open market sales reported on this line occurred at a weighted average price of $448.78 (range $448.18 to $449.12). (F2) Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 8 | Common | Common Stock | 2025-12-03 | S | D | 1,152 | $447.05 | 66,146 | D | — | — | (F8) Open market sales reported on this line occurred at a weighted average price of $447.05 (range $447.00 to $447.23). (F2) Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 9 | Common | Common Stock | 2025-12-03 | S | D | 2,070 | $455.22 | 24,026 | D | — | — | (F14) Open market sales reported on this line occurred at a weighted average price of $455.22 (range $454.88 to $455.66). (F2) Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 10 | Common | Common Stock | 2025-12-03 | M | A | 63,781 | $86.52 | 87,807 | D | — | — | |
| 11 | Common | Common Stock | 2025-12-03 | S | D | 4,469 | $440.40 | 83,338 | D | — | — | (F3) Open market sales reported on this line occurred at a weighted average price of $440.40 (range $440.04 to $441.00). (F2) Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 12 | Common | Common Stock | 2025-12-03 | S | D | 1,320 | $441.26 | 82,018 | D | — | — | (F4) Open market sales reported on this line occurred at a weighted average price of $441.26 (range $441.14 to $442.00). (F2) Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 13 | Common | Common Stock | 2025-12-03 | S | D | 2,469 | $443.21 | 79,549 | D | — | — | (F5) Open market sales reported on this line occurred at a weighted average price of $443.21 (range $442.94 to $443.93). (F2) Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 14 | Common | Common Stock | 2025-12-03 | S | D | 4,352 | $444.36 | 75,197 | D | — | — | (F6) Open market sales reported on this line occurred at a weighted average price of $444.36 (range $444.00 to $444.94). (F2) Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 15 | Derivative | Stock Option (Right to Buy) | 2025-12-04 | M | D | 1 | $0.00 | 0 | D | $91.05 · — to 2026-02-01 | 1 Common Stock | (F15) Fully vested. |
| 16 | Derivative | Stock Option (Right to Buy) | 2025-12-03 | M | D | 63,781 | $0.00 | 0 | D | $86.52 · — to 2027-02-02 | 63,781 Common Stock | (F15) Fully vested. |